Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

PMR 05 - Neurology > Day 2 - Amyotrophic Lateral Sclerosis > Flashcards

Day 2 - Amyotrophic Lateral Sclerosis Flashcards

1
Q

Definition of ALS

A

Disease of UMN (Corticospinal & Corticobulbar tracts) and LMN (Anterior horn cells):

LMN “amyotrophic”

Muscle denervation result in weakness, atrophy, and fasciculations

UMN “lateral sclerosis”

Lateral corticospinal tracts sclerosis result in hyperreflexia and spasticity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Amyotrophic lateral sclerosis (ALS) Etiology, Presentation, Prognosis

A

Pathology

  • Degeneration of the anterior horn cell & UMN spinal tracts

Clinical presentation

  1. Bulbar
    1. Speech: Dysarthria
    2. Swallowing: Dysphagia
    3. Pseudobulbar signs: A cluster of symptoms including difficulty chewing, swallowing, and speech along with unprovoked emotional outbursts (e.g., crying and laughing)
  2. Thoracic: Respiratory failure
  3. Limbs: Asymmetric weakness, Atrophy & fasciculations

Spared

  1. Bowel and bladder
  2. Sensation
  3. Extraocular muscles
  4. +/- Cerebellar
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Prognosis & Mobility of ALS

A

503

  • 50% die within 3 years
  • 30% live for 5 years
  • 10% live for 10 years

Wheelchair by 12–18 months

Average survival from onset 3-5 years (From Dx 15 months)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Diagnostic Criteria for ALS

A
  1. Clinically definite ALS
    • LMN and UMN signs in the bulbar region and at least two spinal regions “OR” three spinal regions without bulbar region.
  2. Clinically probable ALS
    • Evidence of LMN and UMN signs in at least two regions
    • PLUS UMN signs above the LMN signs.
  3. Clinically possible ALS
    • Evidence of UMN + LMN dysfunction in one region
    • UMN alone in two or more regions
    • LMN signs are found rostral to UMN signs.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

List 4 ALS Variants

A
  1. Progressive bulbar palsy (Pure bulbar involvement)
    1. Dysarthria: Slurred speech, hoarseness, or decreased volume of speech
    2. Dysphagia: Aspiration or choking during a meal
  2. Progressive muscular atrophy (Pure lower motor neuron degeneration)
    • Reduced finger dexterity and weakness or wasting of intrinsic hand muscles
    • Wrist drop interfering with work performance
    • Foot drop; patients may report a “slapping” gait
    • Tripping, stumbling when running
  3. Brachial amyotrophic diplegia (BAD)
    • Upper limbs focus
  4. Leg amyotrophic diplegia (LAD)
    • Lower limbs focus
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

List 6 Amyotrophic Lateral Sclerosis-Plus Syndromes

A

Add what is normal + other dx has plus in it.

  • Sensory loss
  • Ocular motility abnormalities
  • Autonomic dysfunction
  • Parkinsonism
  • Extrapyramidal signs
  • Frontotemporal dementia (FTD)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Protocol for ALS in EMG

A

Rule out root or plexopathy

Abnormal EMG result in at least two muscles innervated by different roots and peripheral nerves.

Active denervation with reinnervation must be found in three of four body segments

  1. Craniobulbar (Cranial n.)
  2. Cervical (Arms)
  3. Thoracic (Trunk)
  4. Lumbosacral (Legs)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

EDX Result in MND

A

NCS

  • SNAP: Typically normal
  • CMAP: Abnormal (Motor disease)

EMG

  • Abnormal Activity: FIBs, PSWs, Fasciculations (De-innervation)
  • Decreased MUP recruitment (Damaged motor neurons)
  • Large amplitude MUAP (Re-innervation)

SFEMG

  • Abnormal fiber density, jitter, and blocking. (Mimics NMJ)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Bulbar Symptoms in ALS

A

Speech

  1. Dysarthria: Slurred speech
  2. Dysphonia: Hoarseness

Swallowing

  1. Oral Phase: Difficulty Chewing, Swallowing, Sialorrhea (drooling)
  2. Pharyngeal Phase: Choking & Aspiration
  3. Esophageal Phase: GERD, Vomiting, Malnutrition

Reflex

  1. Absent Gag reflex
  2. Absent Jaw Jerk
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

List 4 DDx for Bulbar Palsy other than ALS.

A
  1. Brain stem stroke
  2. Brain stem tumor
  3. Myasthenia Gravis (MG)
  4. Guillain-Barré syndrome (GBS)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Insufficient caloric intake in ALS can be related to

A
  1. Difficulty transferring food to the mouth due to arm weakness.
  2. Fatigue while eating
  3. Dysphagia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Feeding Management in MND.

A

Diet Type

Using thickener based on IDDSI after swallowing assessment

Diet Route

NGT → PEG tube with high caloric supplements

Low Risk Feeding Strategies

  1. Sit up at 90 degrees
  2. Small amounts
  3. Don’t mix solids and liquids (i.e., mixed consistencies)
  4. Supervision
  5. Remain upright 3o minute
  6. Focus on eating and eliminate any distraction (Tv)

Compensatory Techniques

  1. Chin tuck
  2. Head turn to weaker side
  3. Head tilt to stronger side
  4. Double swallow
  5. Supraglottic swallowing

Clearing Techniques

Mouth wash or manual removal by fingers

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

When do you refer ALS patient for PEG insertion?

A

Monitor FVC every 3 months

  1. PEG Before FVC <50%
  2. Hypocaloric, Dehydration, Weight loss more than 10%
  3. Choking & repeated aspiration pneumonia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

List 4 Pharmacological treatments in Sialorrhea

A
  1. Oral or transdermal scopolamine
  2. Botulinum toxin type A, every 3 months at a dose of 7 to 22.5 units → S/E jaw dislocation
  3. Atropine drops → 0.25 to 0.75 mg 3 times daily
  4. Amitriptyline → 25 to 50 mg twice to 3 times daily
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Risk of respiratory complications in ALS

A

Bulbar Dysfunction

  • Sialorrhea, Aspiration Pneumonia

Respiratory Dysfunction

  • Breathing: Inadequate maintenance of ventilation → Atelectasis
  • Cough & Secretion: Inadequate mucus clearance
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Respiratory complications in ALS. (Another Q: Benefits of pulmonary rehabilitation)

A

Day time

  1. Dyspnea, Tachypnea, Fatigue
  2. Weak cough
  3. Paradoxical breathing

Night Time

  1. Orthopnea
  2. Nocturnal hypoventilation
  3. OSA: Excessive sleepiness, morning headaches or drowsiness, Poor concentration

Physiological

  1. Polycythemia
  2. Pulmonary hypertension.
17
Q

Managment of Respiratory System in ALS/MND

A

Breathing

  1. Beta agonists & anticholinergic bronchodilators
  2. Breath stacking
  3. Lung volume recruitment (LVR)
  4. NIV (BiPAP)
  5. IV (Tracheostomy)

Cough

  1. Huff coughing
  2. Manually assisted cough and the Heimlich maneuver
  3. Mechanical cough-assisting device

Secretion

  1. Normal saline or N-acetylcysteine
  2. Room humidifier
  3. Suction device
18
Q

Coarse of respiratory statues as ALS disease progress?

A
  1. The Practice Parameters of the American Academy of Neurology suggests that all patients with ALS and respiratory symptoms or an FVC less than 50% predicted should be offered the use of Noninvasive positive-pressure ventilation (NIPPV).
  2. Most patients with ALS will at some point develop bulbar symptoms that are severe enough that they will be unable to continue use of NIPPV because of aspiration pneumonia or failure of NIPPV to ventilate the patient effectively despite 24 hour/day use. At this point, consideration for invasive ventilation may be the only option for continued survival.
  3. Unfortunately, invasive ventilation has no effect on the progression of the disease and patients can develop complete paresis of all muscles including the extraocular muscles and develop a “locked-in” syndrome in which no communication is possible.
19
Q
A

Forced vital capacity (FVC) < 50%

Volume of air that can be forcefully and maximally exhaled after deepest inhalation.

Correlates with orthopnea & justify NIV

Peak cough flow (PCF)

Start NIV if PCF < 270mL / min

Associated with poor cough and a high risk of respiratory infection.

Nocturnal desaturations <90% of 1 cumulative minute

Sensitive indicator of hypoventilation

SAO2 <92%

ABGs → CO2 retention

Start NIV if PaCO2 > 45 mmHg

Maximum inspiratory/expiratory pressure (MIP & MEP)

Start NIV if MIP < 60 mmH2O

Sniff nasal inspiratory pressure (SNIP)

Correlates with hypercarbic respiratory failure

20
Q

List 4 Benefits of Lung volume recruitment (LVR)

A
  1. Open → Reduce atelectasis
  2. Clear → mobilize secretions
  3. Clear → improve pulmonary hygiene
  4. Open → improves peak cough flows
21
Q

Indication of invasive ventilation in ALS

A
  1. Use of NIV more than 12 hours per day
  2. Symptoms of dyspnea
  3. Intolerance of NIV with an FVC less than 50%
22
Q

Considering oxygen therapy for neuromuscular disease?

A

Oxygen therapy should almost never be used in patients with ALS. It worsens respiratory symptoms and hypercapnea and can lead to hypercapnic coma or respiratory arrest.

23
Q

Respiratory rehab in motor neuron disease

A

Every 3 months

  1. Monitor PCF > 5 L/sec or >270mL/min for effective cough
  2. Monitor FVC > 50% for functional breathing

Pulmonary Rehab

  • Breathing

Anticholinergic bronchodilator

NIV (BIPAP) to start if FVC <50% or nocturnal desaturation

IV if failed to reach >90% saturation or hypercabnia

  • Cough & Secretion Managment

PCF < 270 mL/min start LVR and manual assisted cough

PCF <160 mL/min or bulbar → mechanical assisted cough, tracheostomy & suction.

24
Q

Motor Symptoms in ALS

A

Upper Limb

  1. Reduced finger dexterity, cramping, stiffness
  2. Weakness or wasting of intrinsic hand muscles
  3. Difficulty with buttoning clothes, picking up small objects, or turning a key.
  4. Patients may develop wrist drop.

Lower Limb

  1. Tripping, stumbling when running
  2. Foot drop, “slapping” gait
  3. Muscle atrophy, waddling gait, genu recurvatum
  4. Spasticity may compromise gait.
  5. Unsteadiness
  6. Painful joint contractures
25
Q

List 4 causes of pain in ALS.

A
  1. Pressure Ulcer → pressure management
  2. Neuropathic Pain → Amitriptyline or Neurontin (gabapentin)
  3. Spasticity → Anti-spasticity, Physical modalities
  4. Contracture → ROM
  5. Cramps → Acetaminophen (1,000 mg every 6 hours) or NSAID
26
Q

Spasticity. Any precautions in ALS?

A

Non-Pharmacological

  • Physical therapy → Slow (30 second sustained), static muscle stretching
  • Positional splinting (watch for pressure areas)

Pharmacological

  • Oral Baclofen → 5 to 10 mg two to three times a day, titrating up to doses of 20 mg four times a day, watch S/E like weakness, fatigue, and sedation.
  • Benzodiazepines → major side effect is respiratory depression
  • Dantrolene → muscular weakness

Surgical

  • Intrathecal baclofen → successful in ALS
  • Botulinum toxin → make sure not to cause dysfunctional weakness
27
Q

ALS patient referred for ALC, what would like to prescribe?

A

Thoracic

  1. Cervical orthoses for head drop

Upper Limb

  1. Wrist-hand orthosis for wrist drop

Lower Limb

  1. Ankle-foot orthoses for foot drop
  2. Quad cane (four point)
  3. Walker (rollator style)
  4. Wheelchair with good cushioning (gelfoam) and support for the spine.
28
Q

List 4 Bathing assisted devices for ALS.

A

Toilet

  1. Grab bars
  2. Commode chair
  3. Raised toilet seat

Bathing

  1. Hand-held showers
  2. Bath tub benches
29
Q

Write PT & OT Plan for ALS in OPD visit.

A

PT

  1. ROM and Strength Ex (Sub-maximal, avoid fatigue)
  2. Aerobic Exercises

OT

  1. Energy conservation
  2. Hand dexterity (writing, cutting, dressing & hygiene)
  3. Transfer and ambulation → Wheelchair or sling
30
Q

Mood and Cognitive Disorders in ALS & Tx

A
  1. Depression
  2. Anxiety

Treatment

  1. TCA: Amitriptyline 25mg daily (Tx Insomnia & Drooling)
  2. SSRI: Cipralex 10mg daily
31
Q

Pharmacological treatment for ALS.

A

Riluzole

MOA: inhibits presynaptic release of glutamate

Dose: 50 mg twice daily

Adverse reactions: dizziness, asthenia, and gastrointestinal disorders, elevated LFTs

Routine monitoring of liver function tests is recommended.

32
Q

Benefits of exercise for ALS.

A
  1. Beneficial effect on mood, psychological well-being appetite, and sleep.
  2. Fighting depression and improving pain tolerance.
  3. Improvement in functional ability, decrease in disability
  4. Reduction in the rate of decline
33
Q

Negative and positive factors affecting prognosis & Average survival.

A

Negative

  1. Female
  2. Old age of diagnosis
  3. Bulbar Onset
  4. Rapid progression
  5. Definite diagnosis of ALS

Treatment affecting prognosis

  1. Percutaneous endoscopic gastrostomy (PEG) tube
  2. Non-invasive ventilation
  3. Riluzole
  4. Multidisciplinary Clinics
34
Q

Negative and positive factors affecting prognosis & Average survival.

A

Treatment affecting prognosis

  1. Percutaneous endoscopic gastrostomy (PEG) tube
  2. Non-invasive ventilation
  3. Riluzole
  4. Multidisciplinary Clinics

Negative

  1. Female
  2. Old age of diagnosis
  3. Definite diagnosis of ALS
  4. Bulbar Onset
  5. Rapid progression
35
Q

Exercise Prescription & Precautions for ALS

A

Exercises

  • Mild-to-modest resistance exercises for 15 minutes twice daily.
  • Resistance training has been shown to improve function and spasticity.
  • Aerobic exercises (Low impact like cycling)
  • Warm pool therapy, walking mid-chest height.
  • Range of motion and stretching exercises are considered safe

Precautions

  1. Fatigue
  2. Dyspnea
  3. Eccentric
  4. Cramps
  5. Prolonged DOMS
  6. Weakness post exercise

Fix → Scale down the exercise plan

PMR 05 - Neurology (7 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions